PMID- 36751934
OWN - NLM
STAT- MEDLINE
DCOM- 20230209
LR  - 20230209
IS  - 2639-9636 (Print)
IS  - 2639-9636 (Linking)
VI  - 38
IP  - 2
DP  - 2023 Feb 1
TI  - New Drug: Tirzepatide (Mounjaro()).
PG  - 50-62
LID - 10.4140/TCP.n.2023.50 [doi]
AB  - Type 2 diabetes mellitus (T2DM) is the most common form of diabetes and is a 
      chronic and progressive illness. Millions of Americans have T2DM and many 
      patients do not achieve the recommended blood glucose levels. Glucagon-like 
      peptide 1 (GLP-1) based therapy is an established treatment for the management of 
      T2DM and is recommended early in the treatment algorithm. GLP-1 therapy is 
      associated with better glycemic control, weight reduction, and favorable 
      cardiovascular outcomes. Tirzepatide (Mounjaro) is a novel dual 
      glucose-dependent insulinotropic polypeptide (GIP) receptor and GLP-1 receptor 
      agonist. Evidence from five SURPASS clinical trials has demonstrated that 
      tirzepatide has potent glucose lowering and weight loss with adverse effects 
      comparable to GLP-1 receptor agonists. This paper gives an overview of 
      tirzepatide and SURPASS clinical trials.
FAU - Gettman, Lana
AU  - Gettman L
AD  - Harding University College of Pharmacy, Searcy, Arkansas.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Sr Care Pharm
JT  - The Senior care pharmacist
JID - 101737969
RN  - OYN3CCI6QE (tirzepatide)
RN  - 0 (Glucagon-Like Peptide-1 Receptor)
RN  - 89750-14-1 (Glucagon-Like Peptide 1)
RN  - IY9XDZ35W2 (Glucose)
SB  - IM
MH  - Humans
MH  - *Diabetes Mellitus, Type 2/drug therapy
MH  - Glucagon-Like Peptide-1 Receptor/agonists/therapeutic use
MH  - Glucagon-Like Peptide 1/therapeutic use
MH  - Weight Loss
MH  - Glucose/therapeutic use
EDAT- 2023/02/09 06:00
MHDA- 2023/02/10 06:00
CRDT- 2023/02/08 03:14
PHST- 2023/02/08 03:14 [entrez]
PHST- 2023/02/09 06:00 [pubmed]
PHST- 2023/02/10 06:00 [medline]
AID - 10.4140/TCP.n.2023.50 [doi]
PST - ppublish
SO  - Sr Care Pharm. 2023 Feb 1;38(2):50-62. doi: 10.4140/TCP.n.2023.50.